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Abstract 
Lens-epithelium-derived-growth factor (LEDGF/p75) is an essential host protein for integration 
of HIV-1 DNA into host genome. Earlier alanine scanning mutational analysis has revealed that 
residues I365, D366 and F406 in the integrase binding domain (IBD) of p75 are critical for 
interaction with HIV-1 integrase (IN), while K364, V408 have intermediate effect and residues 
N367, L368, R405, K407 show wild type binding with IN. To gain insight into contribution of 
side chains of L368 and V408 that are adjacent to critical residues I365 and F406, respectively, 
site directed mutation of these residues to Ile/Leu, Met and Phe has been performed and 
characterized in this study. In contrast to alanine substitution, L368F mutation showed a ~25% 
decrease, while V408L and V408F showed wild type binding, to IN. Docking analysis of I365, 
D366 and F406 mutants of IBD with IN predicts that interaction between residue M178(IN) and 
I365(IBD) might lead to an encounter complex formation. Accordingly, M178I mutant of IN failed 
to interact with IBD. Interestingly, a L368F/V408F double mutant of IBD restored binding to 
M178I mutant of IN, indicating that altered hydrophobicity in the inter helical loops of IBD might 
make I365 more accessible for interaction with IN.    
Keywords: HIV, integrase, LEDGF/p75, inter helical loops, M178, L368. 
Introduction 
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HIV-1 integrase (IN) catalyses a two-step reaction to integrate viral DNA into human genome [1-
4]. The first step is a removal of dinucleotide from 3`ends of viral DNA termed 3`processing and 
the second step termed as strand transfer involves the covalent bonding of the 3`ends into human 
genome. Several host proteins have been identified to be associated with IN and influence its 
activity [5-13]. Lens epithelium-derived growth factor (LEDGF/p75) is an essential host protein 
for integration of HIV-1 viral DNA into host genome. Extensive structural and biochemical studies 
of p75-IN interaction and its effect on activity of IN are known [14-25]. Two inter helical loops in 
Integrase Binding Domain (IBD) of p75 having residues, K364, I365, D366, N367, L368, R405, 
F406, K407 and V408 are the site of interaction with catalytic core domain (CCD) of IN 
[16,17,21,25]. Of these, I365, L368, F406 and V408 form a solvent accessible hydrophobic 
surface. Alanine scanning mutagenesis revealed that I365, D366 and F406 to absolutely critical 
for the interaction [16]. Substitution of K364 and V408 by alanine resulted in an intermediate 
binding.   
Residue I365 of IBD is involved in hydrophobic interactions with the pocket created by side chains 
of L102, A128, W132 and M178 of CCD. In the complex, the delta carbon (CD1) of I365 rotates 
into the hydrophobic pocket of CCD [16,17]. In unbound state, CD1 of I365 is at 4.8oA from CD2 
of L368, which increases to 9.1oA upon binding to IN and the distance between CD1 of I365 and 
CG1 of V408 increases from 6.2oA to 10.5oA. The rotation of CG1-CD1 arm of I365 from 
hydrophobic pocket of IBD to that in IN dimer is critical for IBD-CCD interaction. Additionally, 
hydrophobic interactions are present between F406, V408 of IBD and W131 of CCD. A bidentate 
H-bond involving oxygen of delta carbon of D366 (IBD) and main chain amine of E170 and H171 
of CCD is essential for interaction. A salt bridge involving K364(IBD) & E170(CCD) and 
hydrophobic interaction between V408(IBD) & W131(CCD) provides stability to IBD-CCD 
complex.  
Based on the IBD-CCD co-crystal structure, the steps leading to the rotation of side chain of I365, 
bidentate Hydrogen bond formation by D366 and hydrophobic interaction involving F406 of IBD 
cannot be derived. However, it is reasonable to assume that side chains of residues adjacent to the 
critical residues might provide clues to understanding an encounter complex formation [26]. The 
initial interactions during encounter complex formation between IN and IBD might trigger the side 
chain of I365 to lose contact with the hydrophobic surface comprising of side chains from L368, 
F406 and V408 [17] and gain interaction with the hydrophobic pocket of IN dimer comprising of 
L102, A128, A129, W132 (of chain B) and T174, M178 (of chain A). Mutagenesis of residues 
L368, V408 of IBD and M178 of IN performed in this study, combined with docking analysis, 
indicate that M178(IN)-I365(IBD) interaction could lead to IN-IBD encounter complex formation.  
Materials and Methods 
Mutagenesis  
Mutations were generated using overlap PCR protocol [27]. The plasmids pCP-GST-75-81 [28] 
and pINKB6HThr [14,29] were used as templates for mutagenesis of IBD and IN, respectively. 
All plasmids were sequence confirmed. 
Purification of recombinant proteins 
All proteins were induced in bacterial strain BL21(DE3)pLysS using 1mM IPTG at 28oC for 4h. 
His-tagged IN was purified as described earlier [29,30]. GST tagged IBD was purified as described 
earlier [28] except for use of buffer containing 500mM NaCl, 50mM NaPhosphate buffer (pH 6.5), 
1mM EDTA, 5mM DTT and 0.2mM PMSF. Purified proteins were stored at -20oC with 50% 
glycerol. Multiple batches of each protein were tested in the pull down assays.  
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In vitro pull-down assay 
The IN-IBD pull-down analysis [14,16,28,30-32] was performed in a phosphate pull-down buffer 
(PPD buffer) containing 50mM NaPhosphate buffer (pH 6.5), 150mM NaCl, 2mM MgCl2, 25mM 
Immidazole, 0.1% NP-40. To 150µl of PPD buffer, 6µg of IN and 4.5µg of IBD were added and 
incubated for 10 min at 37oC. Complexes were bound to Ni-sepharose-6-Fastflow beads (GE 
Healthcare) for 30 min, at room temperature. Beads were washed with 5 volumes of PPD buffer 
prior to elution using 400 mM Immidazole and resolved on a 10% SDS-PAGE. Intensity of 
coomassie blue stained protein bands was quantified using Image Lab Software 4.0 (Bio-Rad). 
Computational analysis 
Building of mutants and docking was performed using Discovery Studio version 4.0 software 
(Accelrys, USA). Chains corresponding to IBD in IBD-CCD co-crystal structure 2B4J [17] were 
used for building the mutants and refined for side chains. IBD was docked onto CCD of 2B4J 
structure using ZDock program and poses generated were selected for further analysis based on 
proximity of any of IBD residues I365, D366, F406 and V408 to those of IN at the interface: L102, 
A128, A129, W131, W132, E170, H171, T174 and M178. Non-bond interactions at the interface 
of selected poses were compared to those reported in 2B4J. 
Statistical analysis 
Intensity of bands corresponding to IBD and IN were used to estimate the extent of complex 
formed. The IBD:IN ratio in sample having wt IBD was set to 100% and those having mutant IBD 
were calculated with respect to this. Data from more than three independent experiments has been 
used to obtain standard error.  
Results and Discussion 
Phenylalanine at 368 position affects binding 
L368 of IBD has a hydrophobic interaction with A128 of IN [17]. L368A mutant of IBD was 
shown earlier [16] to not affect binding to IN (Fig 1, lane 5 and table 1). Since alanine scanning 
mutagenesis may not always reveal the significance of hydrophobic side chains [33], to probe if 
sulphur containing Methionine or bulky aromatic side chain of phenylalanine would affect binding 
to IN, L368M and L368F mutants of IBD were analysed. As shown in Fig 1, a decrease of ~25% 
binding of L368F mutant (lane 3) to wt IN was observed compared to wt IBD (lane 1). L368M 
(lane 2) or L368I (lane 4) did not have any effect. The results (table 1) indicate that side chain of 
phenylalanine (F368) might distort the loop having critical residues I365 and D366 or alter the 
orientation of F406 having T-shaped pi-pi interaction with W131 of IN [17].  
Phenylalanine at 408 position retains wild type binding 
V408A mutant of IBD was shown to have an intermittent binding [16], here the binding of this 
mutant has been determined to be 76±1.55% of wt IBD (Fig 1, lane 10). V408M mutant showed 
80±2.9% binding (lane 7), indicating that a sulphur-pi interaction [34,35] between M408 and F406 
could interfere with F406-W131(IN) interaction resulting in a decrease in binding. In contrast, 
V408L (lane 6) or V408F (lane 9) mutant bound similar to wt IBD (table 1). Unlike, F368 that 
could alter orientation of F406 (lane 3), F408 (lane 9) might make stacking interaction with F406 
[36] without disturbing F406-W131(IN) bond. 
F368 affects binding even in presence of F408 
To assess if presence of F408 could counter decreased binding of F368 mutant, L368F/V408F 
double mutant was analysed. However, as can be seen in Fig 1, L368F/V408F mutant showed 
76±2.57% binding (lane 11) similar to that observed with L386F mutant, indicating that F368-
F406 interaction interferes with F406-W131(IN) bond even in presence of F408-F406 interaction. 
The presence of bulky side chains of phenylalanine at three of 4 residues in the hydrophobic 
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surface do not seem to result in a severe structural distortion that would abolish IBD-IN complex 
formation. To analyse for an added effect [37], L368F/V408M mutant was analysed and found to 
have 73±2.9% binding (lane 12), similar to that of L368F mutant. Effect of M408 on orientation 
of F406 (lane 7) appears to be secondary to that at position 368. The binding of single and double 
mutants of IBD to wt IN summarized in table 1 indicates that interfering with orientation of F406 
by side chain at 368 position can have an impeding effect on complex formation.  
Docking analysis predicts M178-I365 bond in encounter complex  
To gain insight into the role of the four residues I365, L368, F406 and V408 of hydrophobic 
surface in formation of complex with CCD, docking analysis of mutants of critical residues, 
namely, I365A, F406A and D366N [16,17] was performed. Table 2 summarizes the interactions 
observed in the docked complex of mutants of IBD with wt CCD, compared to those present in 
the 3D structure, 2B4J [17]. Two interactions are predicted in I365A(IBD)-CCD complex, with 7 
interactions in F406A(IBD)-CCD complex and 13 interactions in D366N(IBD)-CCD complex. 
The interactions present in 2B4J structure have been arranged in an order that reflects initial 
interactions (an encounter complex) between IBD and CCD at the top and subsequent interactions 
in the following rows of table 2. The basis for this arrangement is the rationale that mutation of a 
critical residue (for eg., F406) would not significantly interfere with interactions occurring prior 
to those involving itself, but would abolish any interactions involving the residue (F406 in this 
example) as well as those subsequent to it. The interactions have been divided into 6 steps with 
each step having multiple interactions that cannot be predicted to be occurring in a particular order, 
but would occur prior to those in the next step. Accordingly, step 1 for IBD-IN interaction would 
involve A128(CCD)-L368(IBD) and M178(CCD)-I365(IBD) interaction, which might trigger step 
2 involving W132(CCD)-I365(IBD) and W131(CCD)-F406(IBD) interactions. A similar pattern 
of increased interactions can be derived for step 3 to step 6, till a stable IBD-CCD complex is 
formed. It can be seen that hydrophobic interaction between alkyl side chains of I365(IBD) and 
M178(IN) is an interaction in step 1 (table 2) that is present in all the three mutant IBD-CCD 
docked complexes. Although these three mutants of IBD do not bind to CCD in pull-down assays 
[16], docking analysis has allowed identification of this interaction, as it can predict formation of 
complexes that are not biologically stable or are highly transient [38-40].  
M178I mutant of IN does not bind to IBD 
Based on the prediction that M178(IN)-I365(IBD) is an interaction for IN-IBD encounter complex 
formation (table 2), mutation of M178 of IN to isoleucine, so as to interfere with the extent of alkyl 
interaction with I365 of IBD, was designed. Isoleucine side chain is comparable to Methionine in 
bulkiness and alkyl nature [41], while being shorter by one Carbon-Carbon bond (C-C) length and 
lacking the sulphur atom. Towards forming an encounter complex, if M178(IN) has to initiate the 
rotation of CD1 of I365, one C-C shorter side chain of isoleucine could prove to be inadequate.  
To test this, M178I mutant of IN was generated and analysed for interaction with IBD. Since side 
chain of T174 is adjacent to M178 and is involved in carbon H-bonding [42,43] with D366 of IBD 
[17], T174V mutant of IN was also assayed. Valine lacks the hydroxyl group that imparts H-
bonding ability to beta Carbon of T174 with delta O of D366(IBD). As shown in Fig 2, wt IBD 
showed a 65±3.2% complex formation with T174V mutant (lane 2, top panel) compared to that 
with wt IN (lane 1, top panel), probably reflecting a loss of Carbon H-bond between V174(IN) and 
D366(IBD).  
In line with the prediction that M178(IN)-I365(IBD) interaction could be one of the first steps, wt 
IBD failed to yield complex with M178I mutant of IN (lane 2, bottom panel). Earlier, a M178C 
mutant of IN was shown to have a weak 3`processing and no strand transfer activity [44], however, 
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its interaction with IBD was not analysed. It was concluded that sulphur in the side chain of M178 
is involved in a four-tiered pi-electron orbital interaction along with W132, F181 and F185 and 
that this interaction is critical only for tetramerization of IN required to catalyse strand transfer 
reaction. It is possible that M178I mutation analysed here fails to interact with IBD as the extent 
of hydrophobicity of the cleft formed between the monomers of IN is not sufficient for initiating 
the rotation of side chain of I365(IBD) residue observed in 3D structure, 2B4J [16,17].  
L368F/V408F double mutant of IBD interacts with M178I mutant of IN 
To test if altered hydrophobicity at the surface of IBD comprising of I365, L368, F406 and V408 
might restore interaction with M178I mutant of IN, the single and double mutants of L368 and 
V408 of IBD were analysed for formation of complex. When compared to binding between wt 
IBD and T174V mutant of IN, it was observed that all the mutants of IBD, except for 
L386F/V408F double mutant, showed a trend similar (lower or wt level) to that observed with wt 
IN (Fig 2, top panel and table 1). Exceptionally, presence of three phenylalanine residues at 
positions 368, 406 and 408 (L368F/V408F double mutant) of IBD enhanced the complex 
formation (by ~20%) with T174V mutant of IN (Fig 2, top panel, lane 10) and enabled complex 
formation with M178I mutant of IN (Fig 2, bottom panel, lane 10). Similar to wt IBD, all other 
IBD mutants failed to interact with M178I mutant of IN (bottom panel). Based on the requirement 
for side chain of I365 to rotate from the hydrophobic surface of IBD to hydrophobic cleft of IN, it 
can be speculated from the results shown in Fig 2 that increase in hydrophobicity of the solvent 
accessible surface of L368F/V408F double mutant might make side chain of I365 available for 
interaction with IBD binding cleft of IN, even in the absence of a Methionine at 178 position that 
would initiate a rotation of side chain of I365.  
In conclusion, deviating from the results of alanine scanning mutations performed earlier [16, 17], 
the mutation of V408(IBD) to phenylalanine or Leucine retained wild type levels of binding to IN, 
while phenylalanine at 368 position decreases the binding. The presence of phenylalanine at 368 
or methionine at 408 position might interfere with orientation of side chain of adjacent residue 
F406 and consequently its critical interaction with W131 of CCD. Of significance is the loss of 
interaction between IN and IBD upon mutation of M178 to Isoleucine in CCD. The binding to 
M178I mutant of IN could be restored only by presence of phenylalanine at positions 368, 408 in 
addition to that at 406 (in L368F/V408F double mutant). The study provides basis for encounter 
complex of IBD-IN with M178(IN)-I365(IBD) interaction initiating subsequent interface 
interactions. In the order of events resulting in the formation of a stable IBD-IN complex, 
F406(IBD)-W131(IN) interaction might be predicted to be followed by D366(IBD)-
E170/H171(IN) interaction. The L368F/V408F mutant of IBD and M178I mutant of IN can be 
used in structural analysis to reveal the various stages in formation of a final complex of IBD-IN. 
Such insight will help in understanding formation of protein-protein complexes and designing of 
small molecules that can alter solvent accessible hydrophobic surface of proteins to disrupt protein-
protein interactions [45-47].  
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Figure legends  
Figure 1. Effect of mutations at L368 and V408 of IBD. Wild type (wt) or mutants of IBD were 
assayed for formation of complex with wt IN. The formed complexes were analyzed on a 10% 
SDS-PAGE gel. The mutant of IBD is indicated above the corresponding lane. Lanes from more 
than one gel have been assembled for purpose of representation.  
Figure 2. Effect of T174V and M178I mutations of IN. Top and bottom panels (lanes 2-12) 
show interaction with T174V and M178I mutants of IN, respectively. Lane 1 shows interaction of 
wild type IN and IBD. Lane 2 has wt and lanes 3-12 show mutants of IBD as indicated above the 
lanes. Lanes from more than one gel have been assembled for purpose of representation.  
Table legends 
Table 1. Extent of IBD-IN complex formation. Mutants of IBD are indicated in the left most 
column, wild type IN in middle column and with T174V mutant of IN shown in right most column. 
Percent binding of IBD mutants with wt IN (middle column) and T174V mutant (right column) is 
indicated against each IBD mutant. The binding of wt IBD with wt IN or 174V mutant of IN is set 
to 100% for calculating binding of mutant IBD to respective IN. 
Table 2. Interactions in docked complex of mutant IBD and wild type CCD. Interactions 
occurring between IBD and CCD are divided into six steps shown on the left. The details (column 
2B4J) and type of interactions observed in 3D structure of IBD-CCD [17] are shown next. The 
interactions that were predicted in the docked complex of IBD mutants with wild type CCD are 
marked by a tick against those present in the 3D structure. Monomers of CCD are denoted by A, 
B and IBD by C chain in 3D structure(2B4J). * indicates a pi-alkyl interaction. 
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Table 1. Extent of IBD-IN complex formation. 
IBD mutant Wt IN T174V  IN 
L368M 97 ± 3.10  85 ± 2.22 
L368F 75 ± 1.53 66 ± 3.12 
L368I 98 ± 5.55 106 ± 3.05  
L368A 102 ± 1.50 105 ± 4.86  
V408L 90 ± 2.43 91 ± 5.14 
V408M 80 ± 2.90 73 ± 3.50 
V408F 92 ± 2.79  95 ± 3.67 
V408A 76 ± 1.55 84 ±4.00 
L368F/V408F 76 ± 2.57 97 ± 2.41 
L368F/V408M 73 ± 2.90 83 ± 2.90 
 
Table 2. Interactions in docked complex of mutant IBD and wild type CCD. 
STEP 2B4J Interaction I365A F406A D366N 
1 
B:ALA128 - C:LEU368 Alkyl √   √ 
A:MET178 - C:ILE365 Alkyl √ √ √ 
2 
B:TRP132 - C:ILE365 Pi-Alkyl   √ √ 
B:TRP131 - C:PHE406 Pi-Pi T-shaped   √* √ 
C:LYS364:HA - A:GLN168:O Carbon H-Bond   √ √ 
10 
 
C:LYS360:HZ3 - A:ASP167:OD2 Salt Bridge   √ √ 
3 
A:THR174:HB - C:ASP366:OD2 Carbon H-Bond   √   
C:LYS407:HN - B:TRP131 Pi-Donor H-Bond   √   
4 
B:TRP131 - C:PHE406 Pi-Pi T-shaped     √ 
B:ALA128 - C:ILE365 Alkyl     √ 
B:LYS127 - C:VAL408 Alkyl     √ 
B:ALA128 - C:VAL408 Alkyl     √ 
5 
C:LYS364:HE2 - A:ASP167:O Carbon H-Bond     √ 
B:TRP131:HE1 - C:ARG405:O H-Bond     √ 
C:ILE365:HN - A:GLN168:O H-Bond     √ 
6 
A:HIS171:NE2 - C:ASP366:OD2 Attractive Charge       
A:GLU170:HN - C:ASP366:OD1 H-Bond       
A:HIS171:HN - C:ASP366:OD2 H-Bond       
A:HIS171:HD1 - C:ASP366:OD2 H-Bond       
 
 
 
 
 
 
